Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial

Psychosomatic Medicine

Volumn 66, Issue 5, 2004, Pages 707-713

  Cohen, Lee S ^a   Soares, Claudio N ^a   Yonkers, Kimberly A ^b   Bellew, Kevin M ^c   Bridges, Ian M ^d   Steiner, Meir ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Clinical Global Impression severity; Controlled release; Last observation carried forward; Premenstrual dysphoric disorder; Premenstrual syndrome; Selective serotonin reuptake inhibitors; Visual analog scale

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANORGASMIA; ARTICLE; ASTHENIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GYNECOLOGIC DISEASE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENTAL INSTABILITY; MENTAL STRESS; MOOD; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NAUSEA; OBSERVATION; ORGASM DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUSITIS; SOCIAL INTERACTION; SOMNOLENCE; SYMPTOMATOLOGY; TREMOR; VISUAL ANALOG SCALE; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PAROXETINE; PLACEBOS; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4944264939     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.psy.0000140005.94790.9c     Document Type: Article

References (26)

1. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988;33:340-6.
2. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990;147:1634-6.
3. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32.
4. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women: the Harvard Study of Moods and Cycles. J Affect Disord 2002;70:125-32.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994.
6. Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-9.
7. Steiner M, Brown E, Trzepacz P, Dillon J, Berger C, Carter D, Reid R, Stewart D. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Women Ment Health 2003;6: 71-7.
8. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs 2002;62: 1869-85.
9. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Steiner D. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-34,
10. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E. Parry B, Pearlstein T, Severino S, Stouat A, Stone A, Harrison W. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983-8.
11. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-76.
12. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, Eriksson E. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18: 390-8.
13. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000;356:1131-6.
14. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997;33:771-4.
15. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-44.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare; 1976.
17. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavas J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33;quiz 34-57.
18. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988;18:1007-19.
19. Steiner M, Streiner DL, Steinberg S, et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999;53:269-73.
20. Sheehan DV, Hamett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95.
21. SAS. SAS Institute, Inc. Cary, NC: SAS Institute, Inc.; 2001.
22. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
23. Sundblad C, Wikander I, Andersch B, Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur Neuropsychopharmacol 1997;7:201-6.
24. Yonkers KA, Bellew KM, Rolf TE, Perera PD. Analysis of three large clinical trials in the treatment of PMDD. American Psychiatric Association Annual Meeting. San Francisco, CA, 2003.
25. Bellew KM, Cohen LS, Lambert J, Bridges IM, McCafferty JP. Long-term treatment of PMDD. American Psychiatric Association Annual Meeting. San Francisco, CA, 2003.
26. Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG, Hoven C, Farber L. Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 1997;154: 1734-40.